Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. Company
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 01/27 11:00:00 am
644.7 DKK   +4.29%
11:09aEuropean ADRs Move Higher in Thursday Trading
MT
01/26NOVO NORDISK : JP Morgan remains Neutral
MD
01/26NOVO NORDISK : Goldman Sachs remains its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- products for treating diabetes and obesity (85.1%);

- hemophilia treatment products (7.6%): mainly injections of protein;

- growth hormones (6.1%): used for treatment of growth deficiencies in children;

- hormone replacement products (1.2%): used for treatment of the menopause and prevention of osteoporosis.

Net sales are distributed geographically as follows: Europe/Middle East/Africa (27%), the United Sates (45.6%), China (11.1%), North America (2.6%) and other (13.7%).

Number of employees : 45 323 people.
Sales per Business
20192020Delta
Diabetes and Obesity Care102 840.0084.3%108 020.0085.1% +5.04%
Biopharm19 181.0015.7%18 926.0014.9% -1.33%
DKK in Million
Sales per region
2020
United States57 824.0045.6%
EMEA34 297.0027%
Rest of the World17 448.0013.7%
China14 084.0011.1%
Canada3 293.002.6%
DKK in Million
Managers
Name Title Age Since
Lars Fruergaard Jorgensen President & Chief Executive Officer 55 2017
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President 50 2018
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President 61 -
Henrik Ehlers Wulff Senior Vice President-Diabetes API 51 2008
Stephen Gough Global Chief Medical Officer - 2015
Marcus Schindler Senior Vice President-Global Drug Discovery 55 2018
Maziar Mike Doustdar Senior Vice President-International Operations 51 2013
Elizabeth Anne Hewitt Independent Director 65 2012
Sylvie Louise Grégoire, Dr. Independent Director 60 2015
Brian F. Daniels, Dr. Independent Director 62 2016
Members of the board
Name Title Age Since
Helge Lund Chairman 59 2018
Anne Marie Handrup Kverneland Director 65 2000
Stig Strøbæk Director 57 1998
Elizabeth Anne Hewitt Independent Director 65 2012
Jeppe Fonager Christiansen Vice Chairman 62 2013
Sylvie Louise Grégoire, Dr. Independent Director 60 2015
Brian F. Daniels, Dr. Independent Director 62 2016
Kasim Kutay Member-Supervisory Board 56 2017
Mette Bøjer Jensen Director 46 2018
Thomas Rantzau Director 49 2018
Shareholders
NameEquities%
Novo Holdings A/S (Investment Company) 116,129,000 6.55%
Norges Bank Investment Management 43,498,435 2.45%
The Vanguard Group, Inc. 42,586,026 2.40%
Novo Nordisk A/S 32,204,276 1.82%
BlackRock Fund Advisors 27,793,607 1.57%
Capital Research & Management Co. (World Investors) 21,716,186 1.23%
Fundsmith LLP 20,525,100 1.16%
BlackRock Investment Management (UK) Ltd. 19,440,580 1.10%
Handelsbanken Fonder AB 12,656,765 0.71%
BlackRock Advisors (UK) Ltd. 11,994,117 0.68%
Holdings
NameEquities%Valuation
NOVO NORDISK A/S (NOVO B) 32,204,276 1.82% 3,606,714,026 USD
NNIT A/S (NNIT) 4,375,000 17.5% 76,529,819 USD
INNATE PHARMA (IPH) 9,817,546 12.4% 49,659,798 USD
Markets and indexes
- Main Market Large
- OMX Copenhagen 20 / Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, PEA, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  NOVOB:DC
- Reuters Code :  NOVOb.CO
- Datastream Code :  DK:NON
Company contact information
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsvaerd

Phone : +45 44 44 88 88
Fax : +45 44 49 05 55
web site : http://www.novonordisk.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Novo Nordisk A/S
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
NOVO NORDISK A/S-15.89%213 450
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
ELI LILLY AND COMPANY-13.89%215 642
MERCK & CO., INC.3.26%199 903
NOVARTIS AG-2.64%189 740
ASTRAZENECA PLC-2.27%177 586
BRISTOL-MYERS SQUIBB COMPANY-0.18%138 151
SANOFI3.79%130 219
AMGEN INC.-1.08%125 349
GLAXOSMITHKLINE PLC1.57%110 966
BAYER AG9.68%57 141
CHUGAI PHARMACEUTICAL CO., LTD-1.02%53 161
TAKEDA PHARMACEUTICAL COMPANY LIMITED5.45%45 060
DAIICHI SANKYO CO., LTD.-11.11%43 582
JIANGSU HENGRUI MEDICINE CO., LTD.-18.97%42 423
ASTELLAS PHARMA INC.0.72%30 528
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-18.88%19 826
YUNNAN BAIYAO GROUP CO.,LTD-13.30%18 838